key: cord-0926516-84zdjjkg
authors: Shaker, Marcus S.; Mosnaim, Giselle; Oppenheimer, John; Stukus, David; Abrams, Elissa M.; Greenhawt, Matthew
title: Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times
date: 2020-05-14
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2020.05.007
sha: 67bd597aecee2a10af3e59f2462d1c544a2e6bd8
doc_id: 926516
cord_uid: 84zdjjkg

Abstract Background Allergen immunotherapy is safe and effective but is typically administered under strict clinic observation to mitigate risk of a systemic reaction to immunotherapy (SRIT). However, in the setting of the global COVID-19 pandemic, alternative care models should be explored. Objective To evaluate the cost-effectiveness of home immunotherapy self-administration (HITSA) in a highly idealized circumstance for provision of maintenance allergen immunotherapy in a shelter-in-place or other scenarios of unforeseen reduction in non-essential medical services. Methods Markov modeling was used to compare in-office clinic allergen immunotherapy in selected patients using cohort analysis and microsimulation from the societal and healthcare perspectives. Results Assuming similar SRIT rates, HITSA was found to be a cost-effective option with an incremental cost-effectiveness ratio (ICER) of $44,554/QALY (quality adjusted life year) when considering both incremental epinephrine autoinjector (EAI) costs and COVID-19 risks. Excluding EAI costs, HISTA dominated other options. However, outside of pandemic considerations, HITSA was not cost effective (ICER $198,877,286) at annual EAI costs above $287. As the incremental HITSA SRIT rate increased above 15%, clinic AIT was the most cost-effective strategy. Excluding both pandemic risks and risk of motor vehicle accident fatality from round-trip clinic transit, clinic AIT dominated other strategies. Clinic AIT was the more cost-effective option at very high fatality relative risk for HITSA or at very low annual risk of contracting COVID-19. Conclusion Under idealized assumptions HITSA can be a safe and cost-effective option during a global pandemic in appropriately selected patients provided home rates of SRIT remain stable.

Due to the global COVID-19 pandemic, we must take drastic and unprecedented steps for acute 140 service reduction to execute life-saving social distancing strategies.(1) Given rapid community 141 spread from both symptomatic and asymptomatic patients (2, 3), the WHO declared SARS-CoV-142 2 a global pandemic on March 11, 2020 and the President of the United States declared a state of 143 national emergency on March 13, 2020.(4, 5) Provincial, but not national emergencies have 144 been declared in Canada. A worldwide strategy of social distancing and/or quarantine has been 145 implemented to attempt to limit the spread of SARS-CoV-2(6, 7). This strategy includes closure 146 of non-essential businesses and services, including postponement of non-essential medical care circumstances, alternative care models should be considered. We evaluated a model in which 161 patients could be considered for home immunotherapy self-administration (HITSA) if specific 162 criteria are met. These specific criteria include patients that are advised of the risks and benefits 163 and provide informed consent, do not have a history of prior systemic reactions to 164 immunotherapy (SRIT), lack comorbidities complicating anaphylaxis severity and/or treatment, 165 have high health literacy, and are appropriately educated on storage/handling/administration of 166 AIT (and felt to be able to handle these responsibilities in the opinion of the prescribing 167 clinician). (1, 11) In a landscape that requires ongoing contingency planning for potential long-168 term service adjustments (and disruption) to providing standard of care, there are limited data to 169 better inform the range of health and economic consequences of offering HITSA to select 170 patients during the COVID-19 pandemic. The cost-effectiveness of HITSA has not been 171 previously explored. This analysis was undertaken to further characterize this approach to 172 providing a valuable core allergy/immunology service when access to in-person encounters may 173 not be feasible or possible, as well as a supplemental model to assess the feasibility of this 174 approach for venom immunotherapy (VIT). 175

Model Structure: 178

TreeAge Pro (Williamstown, Massachusetts) was used to build a decision tree incorporating 179 costs and probabilities that patients would experience with home immunotherapy during the 180 2020 pandemic. Markov cohort evaluations and microsimulations were used, as this model 181 structure allows evaluation of health state transitions reflective of real-world outcomes. The base 182 case scenario was represented by a 30-year-old patient with allergic rhinitis (AR) who lives five 183 miles from clinic and is transitioned to HITSA for a duration of four years of treatment. 184 and immunotherapy fatalities in each strategy. The microsimulation (n=10,000) discontinued 208 AIT in patients with more than 2 systemic reactions, and patients receiving HITSA had a 25% 209 reduction in patient-preference AIT discontinuation rates. Because patient-level data is not 210 available for inputs, both the base-case cohort and microsimulation used point estimates for 211 inputs described in Table 1 In the base-case, patients began the simulation with moderate AR, which improved to mild AR 298 with the use of AIT (eFigure 1). The baseline health state utilities of moderate and mild AR 299 were 0.864 and 0.880, respectively, based on a study by Retzler et. al., who used year of health relative to the condition of interest. 304 305

Practice variation exists within AIT administration, and as such models evaluated ranges in AIT 307 discontinuation.(28, 29) Patients in cohort evaluations continued AIT regardless of the number of 308 prior SRITs; however, patients in the microsimulations discontinued AIT if they experienced two 309

SRITs. Because the face-to-face requirement may variably create a barrier to AIT, the cohort 310 simulation did not assume in-clinic administration had any impact on adherence or 311 discontinuation rate, but the microsimulation accounted for less attrition in patients receiving 312 HITSA by assuming a 25% reduction in patient-preference AIT discontinuation rates. Sensitivity 313 analyses evaluated a wide range of epinephrine costs and fatality risk-reduction associated with 314 clinic-observed AIT with deterministic sensitivity analyses performed on all variables. Clinic 315 administered fatality reduction was based on a prior cost-effectiveness analyses using similar 316 methodology and included an upper limit assumption of 1000x fatality reduction associated with 317 clinic-observed administration. (37-41) An additional sensitivity analysis explored a 2-fold 318 differential rate of HITSA SRIT due to dosing errors. Probability sensitivity analysis (PSA) were 319 performed incorporating stochastic effects of variable selection across sensitivity ranges using 320 triangular modal distributions around the base-case value. 321 322 Additional PSA was performed using alternate number seeding and alternative gamma 323 distribution parameters for costs with beta distributions for probabilities of hospitalization and 324

SRIT. For alternative modeling as patient level data was not available, gamma distributions 325 assumed standard deviation equivalent to one-half mean values and probability of hospitalization 326 modeled by setting alpha equivalent to the number of event (r) and beta corresponding to the 327 population at risk not experiencing hospitalization (n-r). The probability of SRIT was modeled 328 using a mean annual event rate of 4% with standard deviation set to 0.5%. 329 330

A supplemental model was evaluated for home (HOMVIT) vs. clinic VIT during the pandemic. 332

For this analysis, immunotherapy costs were assumed to be equivalent for home and clinic 333 administration and the base case patient receiving HOMVIT was assumed to be in the first year 334 of a maintenance program of immunotherapy (12 injections per year in the base case with 335 sensitivity analysis to 4 injections per year) adherent to a 5 year VIT course providing persistent 336 benefit. Ongoing VIT was assumed to be completely protective from anaphylaxis, and the risk 337 for anaphylaxis from discontinued immunotherapy assumed to be 50%. Anaphylaxis fatality risk 338 (modeled at 0.29%) was based on a population based epidemiologic study of three national 339 databases published by Ma et. al.(42) , who reported mortality rates of 0.25% to 0.33% for 340 patients hospitalized for anaphylaxis or evaluated in the ED for this diagnosis. Annual sting risk 341 was assumed to be 5%.(43) Health state utility of venom allergy (untreated due to 342 discontinuation of VIT) was assumed to be 0.91 based on standard gamble assessment of severe 343 allergic reaction utility values from Carrol and Downs. (44) In a VIT model, HOMVIT was also cost-effective. In the cohort analysis from a societal 412 perspective, both clinic VIT and HOMVIT were more effective than VIT discontinuation 413 (HOMVIT 25.3557, clinic VIT 25.3538, VIT discontinuation 23.0417). The incremental cost of 414 clinic VIT was $1,485, and HOMVIT remained cost-effective unless the differential rate of SRIT 415 was quadrupled. HOMVIT remained preferred unless HOMVIT related fatality risk exceeded 416 800-fold, differing from the AIT analysis due to the fact that EAI costs were held equal between 417 groups in the supplemental VIT analysis. As with HITSA, as the differential rate of HOMVIT 418 can be cost-effective options. Both HITSA and HOMVIT could be considered as a preference-432 sensitive decision for highly selected patients meeting the criteria laid forth in the base case, 433 20 provided clinic infrastructure is established to support this method of care delivery. However, 434

there are practical issues that may limit immediate implementation relating to patient education, 435 adherence, and infrastructure. In addition, patients would need close monitoring and if home 436 SRIT rates increase HITSA would need to be reconsidered. In the decision model evaluated, 437 patients experiencing HITSA SRIT were transitioned back to a clinic AIT strategy. This analysis 438 may provide clarity in considering these options as a way to continue immunotherapy during this 439 pandemic; however, many clinics may not have necessary protocols in place to support a home 440 administration option urgently. 441

While HITSA was not cost-effective when analyzed from the contextually specific healthcare 443 perspective using a cohort approach except at very low EAI device price, this perspective is 444 narrow and excludes other common societal costs not directly related to the medical service. 445

Alternative modeling in this context using microsimulation did denote possible cost-446 effectiveness, with the microsimulation accounting for the potential of improved adherence with 447 HITSA. HOMVIT was robustly cost-effective, given that a key difference was no additional 448 EAI unit cost in the model vs. in clinic administration. 449

The HITSA cost-effectiveness is dependent on a very narrow set of assumptions and is sensitive 451 to multiple levers ( Figure 5 ). While the risk of contracting a pandemic infection is a significant 452 lever, it is of note that HITSA would also be cost-effective outside of a pandemic as long as EAI 453 device price is below $287. HITSA is highly sensitive to higher wage earners, where home 454 administration mitigates the opportunity cost of time away from their job to receive AIT, and to 455 keeping the cost to administer HITSA low, given a threshold at which in-office administration is 456 favored. There are also a defined range of safety-related concerns contributing to HITSA cost-457 effectiveness. HITSA remains cost-effective vs. in-office administration as long as SRIT fatality 458 risks do not exceed 74-fold greater than the in-clinic risk; however, at a 15% increased HITSA 459 SRIT rate, clinic AIT is the most cost-effective option. A key lever is EAI device price, which is 460 unrelated to AIT itself. In the non-pandemic societal perspective, the pandemic healthcare 461 perspective models, and in one-way sensitivity analysis, the viability of HITSA cost-462 effectiveness hinges on EAI device acquisition price being far below current market value 463

(which was previously shown to have a value-based ceiling price of $24).(41) Herein lies a key 464 difference between administration routes-while for routine office AIT, universal EAI 465 prescription in someone without a history of SRIT is not cost-effective(12), in HITSA universal 466 EAI prescription would be necessary. This reinforces continued negative effects from exorbitant 467 EAI device pricing(45), and is unequivocally a lever that could be changed through advocacy or 468 payer pressure on device manufacturers, which may potentially lower healthcare costs and 469 increase access to a service. The HOMVIT model is not affected by device price given all VIT 470 patients have an EAI. 471 472 HITSA and HOMVIT may raise the question of "just because you can, doesn't mean you 473

should." During a pandemic, HITSA and HOMVIT (even for highly selected patients) would 474 both be a fundamental evolution, which may alter current AIT revenue streams and pose a 475 significant barrier to implementation. Revenue issues, sustainability and penetration of service, 476 and physician acceptability, may all require some adjustment. There are also concerns regarding 477 safety of administration and how to identify the optimal patient for HITSA/HOMVIT. 478

Immunotherapy would still be mixed and administered by the office staff in the first year, and 479 22 mixed but just not clinic-administered thereafter. This could be countered by an increase in 480 patients who may opt for AIT with a HITSA option available. HOMVIT may help increase VIT 481 adherence though the rational for starting VIT is distinctly different than AIT. This safety issue 482 must also be addressed. HITSA and HOMVIT are modeled only as maintenance therapy, in an 483 adherent and well-screened population without history of SRIT, and with good contextual 484 knowledge, high health literacy, and ability/willingness to rapidly self-administer EAI (1 or 2 485 doses) if a SRIT occurs. There would have to be a screening tool developed to help identify 486 patients who are ready for this transition, a patient decision-support tool for considering this 487 option, and some increase in nursing education for patients during the buildup phase to improve 488 familiarity with the injection process, thereby reducing dosing and administration errors. Visiting 489 and telemedicine nursing services could be considered, though this would have to stay within a 490 certain price for the therapies to remain cost-effective and would depend on local social 491 distancing strategies in place. 492

AIT and VIT are safe therapies with overall low rates of SRIT. All patients on the HITSA and 494

HOMVIT therapies would have an EAI device and training in their use. Models could also be 495 explored where the maintenance dose is drawn up at the office and mailed to a patient, to reduce 496 dosing errors. However, we can use examples of several models of homecare where medications 497 of similar potency and potential for significant adverse events are routinely given at home, some 498 daily. A notable example of this is insulin, which is given multiple times a day, and has life-499 threatening potential of harm similar to any form of AIT if given incorrectly. Patients with 500 diabetes are given intensive education to support safe and proper administration at home as 501 routine practice. Provided education is appropriate, there is every reason to think that 12 502 maintenance injections could be handled as such in a pandemic setting, in select patients. To 503 contextualize risk, the estimated rate of AIT fatality per injection, 1.3 x 10 -7 , is on par with the 504 estimated risks of fatal penicillin anaphylaxis (8.0 x10 -8 ) (46), per-patient omalizumab fatality 505 (5.8 x 10 -6 ) ((42, 47, 48) , and the general population risk of home-peanut introduction in US 506 infants (0.3-3 x 10 -7 )(49)(eFigure 4). Penicillin is administered without mandated routine 507 medical observation in the general population, omalizumab is approved for preference-sensitive 508 home administration after the first four uneventful doses in Europe at provider discretion for 509 patients with appropriate indication, and young infants routinely have peanut introduced at 510 home.(46, 50-52) 511

Most importantly, this model is formulated as a direct response to the COVID-19 pandemic that 513 is causing service disruption and forced changes in healthcare service utilization and provides a 514 promising approach to preserve as much normal service as possible in select patients. It is an 515 option to consider, and not formally endorsed by any professional societies or national guidelines 516 at this time. While these cost-effectiveness models for HITSA and HOMVIT are not designed to 517 provide a practical 'how to' guideline on how to implement this scenario, the discussion herein 518 can all be considered if this model is adopted. Regardless of the acceptability of this approach by 519 allergists and patients, the standard manner of delivering AIT to patients in the setting of global 520 pandemic must be significantly altered. At the very least, patient receiving AIT or VIT should be 521 contacted to discuss the ongoing infectious risks associated with continued in-office AIT/VIT 522 visits, and office steps to mitigate such risks. Allergists should also initiate discussion regarding 523 interruption in AIT dosing schedules, including the potential for symptoms to worsen as well as 524

alterations to the AIT schedule if/when injections are resumed, which may necessitate more 525 frequent visits to build back up to the dosing at the time of interruption and additional indirect 526 costs associated with time lost from work, copayments, etc. At the time of this writing, several 527 states and municipalities have mandated interruptions in outpatient office visits, which are 528 expected to increase across North America as the COVID-19 pandemic broadens in scope. 529

Whether allergists agree with or are prepared for these realities, they may be forced into a 530 situation where face-to-face office visits must cease. Preparation and consideration of these 531 elements can assist planning should drastic measures be necessary. 532

The analysis has some limitations. Foremost, the model is deliberately very narrow as to the type 534 of patient entered into the simulation-younger and no history of SRIT. Asthma severity and 535 other co-morbidities were deliberately excluded, and we created a fairly ideal patient type for 536 parsimony in this proof of concept model. This limits generalizability to a number of other 537

scenarios, but this model is meant to introduce the feasibility and cost-effectiveness of the 538 concept, and additional models are required to broaden its application. Secondly, the model is 539 dependent on having an adherent, health literate, and contextually aware patient. There will need 540 to be a significant upgrade to nursing support to educate patients, as well as creation of decision-541 support and other tools to help identify ideal patients (including screening for health literacy), 542 but this can be achieved. However, while our model cannot precisely quantify the importance 543 and potential difficulty in selecting such patients, this is critical. Prior to adopting 544 HITSA/HOMVID, it is crucial to develop home protocols to ensure proper administration, 545 appropriate observation, and clear understanding of necessary activity restrictions-a situation 546 not dissimilar to that for oral immunotherapy. Moreover, patients would need to have access to 547 emergency medical services in the event of an SRIT, and an understanding of when these 548 services should be activated. This may pose limitation in some more rural settings. Third, as 549 the potential for a higher rate of incremental discontinuation in the HITSA model increases, the 550 strategy becomes less cost-effective (and it is possible adherence may decrease with home 551 allergen immunotherapy, though this will have to be monitored closely to better understand how 552 this affects adherence). Fourth, this model does not account for clinician or patient acceptability. 553

Fifth, the most appropriate scenario for deployment of these models (if systems are in place to 554 support it) is during a pandemic, such as COVID-19, where shelter-in-place orders are in effect, 555 social distancing/quarantining is mandated, and non-essential face-to-face healthcare services 556 have been reduced (e.g. "red zone conditions"). That said, with EAI device costs less than $287, 557

HITSA could be cost-effective outside such conditions, and the models are exceptionally 558 sensitive to EAI price and potential supply chain disruptions, a sixth key limitation. Seventh, 559 this model only pertains to maintenance AIT and VIT, but the assumptions and ranges of 560 sensitivity are broad enough and simulated out to weekly injections that could potentially serve 561 as a model for this in certain phases of buildup, though that may require additional modeling. 562

Eighth, the base assumptions are sensitive to current (and low) rates of SRIT that are equivalent 563 between home and clinic administration, but HITSA remains the more cost-effective option 564 when fatality associated from SRIT does not exceed 74-fold that of the in-office rate, and 565

HOMVIT until this exceeds 800-fold. Ninth, we did not evaluate downstream consequences of 566 clinic AIT during the pandemic including increased risk of secondary and tertiary community 567 spread of SARS-CoV-2 from asymptomatic carriers receiving clinic AIT; however, this aspect of 568 compromised social distancing would only serve to accentuate the cost-effectiveness of HITSA. 569

In the normal setting, HITSA and HOMVIT models may not be preferred practice. However, in 571 the midst of an unimaginable global pandemic, where major service disruptions are occurring 572 and likely to continue, rethinking how healthcare can be delivered provides the opportunity to 573 preserve ongoing patient care. HITSA and HOMVIT, under the right assumptions and used in 574 the right patients, can be done safely, providing a valuable service option for our patients. In the 575 setting of the current pandemic, this is an avenue that some clinicians may choose to discuss with 576 selected patients, and this analysis serves as a catalyst for possible shared decision making in the 577 appropriate context. While additional modeling is required to more robustly explore the 578 sensitivity and generalizability of other patient groups and scenarios, creative thinking and a 579 willingness to adapt may prove to be a most valuable resource that the field can mobilize to 580 persevere under less than ideal circumstances. Clear, concise and evidence-informed risk 581 communication is essential, especially in the time of a global pandemic. This study provides a 582 framework through which physicians can consider relative risks and benefits contextually of a 583 novel approach to preserve patient care while maintaining safety in unprecedented times. 

There is a pandemic and non-essential medical care is reduced There are shelter-in-place orders for our patients Figure 5 :

COVID-19: 588 Pandemic Contingency Planning for the Allergy and Immunology Clinic

Proclamation on declaring a national emergency concerning the novel coronavirus 598 disease (COVID-19) outbreak

COVID-19 and Italy: what next? Lancet

Interventions to mitigte early spread of SARS-603

CoV-2 in Singapore: a modelling study. The Lancet Infectious Diseases

Characteristics of and Important Lessons From the Coronavirus 606 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the 607

Chinese Center for Disease Control and Prevention. JAMA. 2020

Self-isolation, quarantine and California's stay-at-home order: What the terms mean 611 and how they differ. CNN health

Allergen 615 immunotherapy: a practice parameter third update

The cost-effectiveness of requiring universal 618 vs contextual self-injectable epinephrine autoinjector for allergen immunotherapy

United States Life Tables

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness 624 Analyses: Second Panel on Cost-Effectiveness in Health and Medicine

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement

Available from: 630 www.bls/gov

Allergy immunotherapy: reduced health care 632 costs in adults and children with allergic rhinitis

Healthcare costs 634 for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study

Risk factors for severe anaphylaxis in 639 patients receiving anaphylaxis treatment in US emergency departments and hospitals

Commercial claims costs 642 related to health care resource use associated with a diagnosis of peanut allergy

Delayed Reactions, and 651 Use of Epinephrine Autoinjectors

Evidence of 654 adherence to allergen-specific immunotherapy

Allergy immunotherapy adherence and delivery route: 657 location does not matter

A comparison of attrition rates in patients undergoing 659 sublingual immunotherapy vs subcutaneous immunotherapy

A Retrospective Study of Clinical 662

To Beat COVID-19, Social Distancing Is A Must. NIH Director's Blog

Severe Outcomes Among Patients with Coronavirus Disease

Utility elicitation in 677 adults and children for allergic rhinoconjunctivitis and associated health states

QALYs in 2018-Advantages and Concerns

An economic evaluation of immediate vs 682 non-immediate activation of emergency medical services after epinephrine use for peanut-683 induced anaphylaxis

e1. 686 39. Shaker MS, Greenhawt MJ. Analysis of Value-Based Costs of Undesignated School Stock 687

Epinephrine Policies for Peanut Anaphylaxis

Cost-Effectiveness of Stock Epinephrine Autoinjectors on 689 Commercial Aircraft

Association of Fatality Risk With Value-Based Drug Pricing of 691

Epinephrine Autoinjectors for Children With Peanut Allergy: A Cost-effectiveness Analysis. 692 JAMA Netw Open

Case fatality and population mortality associated with 694 anaphylaxis in the United States

The utility assessment method order influences 699 measurement of parents' risk attitude. Value Health

Economic evaluation of epinephrine auto-injectors for 701 peanut allergy

Who needs penicillin allergy testing?

Xolair (omalizumab) Highlights of Prescribing Information

Estimation of 707 Health and Economic Benefits of Clinic Versus Home Administration of Omalizumab and 708 Mepolizumab

Novartis receives European Commission approval for self-administration of Xolair across 712 all indications

Addendum 715 guidelines for the prevention of peanut allergy in the United States

Institute of Allergy and Infectious Diseases-sponsored expert panel

Australian Consensus on Infant Feeding Guidelines to Prevent Food Allergy: Outcomes From the 720

Australian Infant Feeding Summit

The base case scenario was represented by a 30-year-old patient with allergic rhinitis 726 (AR) who lives 5 miles from clinic, receiving maintenance AIT, with no history of prior systemic 727 reaction, excellent adherence, contextual knowledge, and high health literacy transitioned to 728 home AIT for 4 years. Cohorts of patients were randomized to three strategies: (i) Clinic-729 administered AIT with 30-minute observation

Figure 2: Tornado diagram of one-way sensitivity analyses comparing strategies of HITSA vs 732 clinic AIT during the COVID-19 pandemic

Blue bars represent values below and red bars 734 those above base case assumptions. Values in parenthesis represent range of changes 735 explored. Changes associated with positive gain in NMB are cost-effective at a WTP of 736 $100

Sensitivity analysis of HITSA fatality risk increase during the COVID-19 pandemic. 739 Legend: Dotted line represents the threshold at which the net monetary benefit (NMB) of clinic 740 AIT exceeds HITSA

HITSA was the most cost-effective strategy

Summary Overview of Key Findings 747 Legend: Summary diagram of the key assumptions and constraints in analyzing the cost-748 effectiveness of home allergen and venom immunotherapy

Repository Figure Legends eFigure 1. Health State Transition Diagrams Legend: Transitions within the HITSA cohort are shown for HITSA (panel a) and clinic AIT

Sensitivity analysis of incremental risk of COVID-19 infection from visiting allergy clinic for immunotherapy. Legend: Dotted line represents the threshold at which the net monetary benefit (NMB) of HITSA exceed clinic AIT. Note: axes do not start at 0. eFigure 3: Cost-effectiveness curve

Estimated rates of fatal venom, drug, and food anaphylaxis in the general population compared with other risks

Allergen immunotherapy (annual cost)$524 $200 -$1, 200 Hankin et. al., 2013 17 Annual healthcare cost reduction from AIT 37.6% 10% - 50% Hankin et. al., 2013 17 Self-injectable epinephrine (